Analyzing HLA in Autoimmune Encephalitis and Related Disorders
Immunogenetic Characteristics in Autoimmune Encephalitis and Related Disorders: HLA Analysis: Part II
This study is trying to see if certain antibodies in the blood or spinal fluid of people with autoimmune encephalitis and related disorders can help doctors better understand their symptoms and improve their care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 700 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 1 site (Bron) |
| Trial ID | NCT04823728 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS), which are immune-mediated conditions associated with cancer. It aims to analyze the presence of specific autoantibodies in patients' serum or cerebrospinal fluid and correlate these findings with clinical presentations. The study will include patients with well-characterized antibodies and a compatible clinical picture, while excluding those with incomplete data or incongruences. By understanding the relationship between these antibodies and neurological symptoms, the study seeks to enhance diagnostic accuracy and patient management.
Who should consider this trial
Good fit: Ideal candidates include individuals with confirmed autoantibodies and clinical symptoms consistent with autoimmune encephalitis or paraneoplastic neurological syndromes.
Not a fit: Patients without well-characterized antibodies or those with incongruent clinical presentations may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the diagnosis and treatment strategies for patients with autoimmune encephalitis and related disorders.
How similar studies have performed: Other studies have shown success in identifying autoantibodies in autoimmune encephalitis, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Presence of well-characterized antibodies in serum or cerebrospinal fluid; * Clinical picture compatible with the detected antibody based on the literature; * For PNS, cancer detected and compatible with the detected antibody based on the literature Exclusion Criteria: * Absence of complete clinicobiological data. * Incongruences between antibody-clinics or antibody-cancer
Where this trial is running
Bron
- Hôpital Neurologique — Bron, France (Recruiting)
Study contacts
- Study coordinator: Jerome HONNORAT, MD
- Email: jerome.honnorat@chu-lyon.fr
- Phone: 4 72 35 78 08
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.